A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...
The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
The assay is designed to encourage informed patient-physician decision-making when choosing a treatment option in localised ...
A prostate cancer committee has been accused of exaggerating the risks of screening. Advisers to Wes Streeting, the Health ...
An independent group of medical experts with the U.S. Preventative Services Task Force recommends that men of all ages no longer be screened using the prostate-specific antigen blood test to check for ...
Scientists comment on the Prostate Cancer Research report that reviews the economic model used to inform decisions on prostate cancer screening in the UK. Prof Hashim Ahmed, Professor of Urology, ...
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results